Definium Therapeutics Return on Equity

Definium Therapeutics (DFTX) currently reports a ROE of -38.51%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Definium Therapeutics's ROE history and peer comparisons.

Definium Therapeutics's ROE of -38.51% is lower than the Healthcare sector average of 22.76%. That is roughly 269.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Definium Therapeutics's current -38.51% should be judged against Healthcare norms (sector average: 22.76%) and against DFTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -38.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Definium Therapeutics, and consider following DFTX for alerts when major investors trade the stock.

Definium Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -38.51% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DFTX with unrelated industries.